RBC Capital Remains a Hold on PPG Industries (PPG)
RBC Capital analyst Arun Viswanathan maintained a Hold rating on PPG Industries (PPG – Research Report) yesterday and set a price target of ...
RBC Capital Reaffirms Their Buy Rating on Beacon Roofing Supply (BECN)
RBC Capital analyst Michael Dahl maintained a Buy rating on Beacon Roofing Supply (BECN – Research Report) today and set a price target of ...
RBC makes two changes to its ‘Global Energy Best Ideas’ list
RBC Capital Markets head of global energy research Greg Pardy has made two changes to his Global Energy Best Ideas list, ...
RBC maintains Beacon Roofing stock Outperform with $130 target
RBC Capital Markets reiterated their Outperform rating on Beacon Roofing Supply (NASDAQ:BECN) with a steady price target of ...
RBC maintains Outperform on Spectrum Brands stock, $114 target
RBC Capital Markets sustained its positive stance on Spectrum Brands Holdings Inc . (NYSE:SPB), maintaining an Outperform rating with a steady price target of $114.00. According to InvestingPro ...
Biggest of the Big Six: How RBC opened a $100-billion market-cap gap over its banking rivals
J.M. Smucker Co. chief executive Mark Smucker leaned on close advisers when he made the decision to bolster the jelly and ...
Financial Services Roundup: Market Talk
Find insight on BNP Paribas, UBS, Kasikornbank and more in the latest Market Talks covering Financial Services.
U.K. March 2030 Gilt Trades Cheap, But Supply Schedule Dims Its Appeal
The U.K. March 2030 gilt traded at a historically cheap level and could attract some demand at Tuesday’s auction, RBC Capital Markets said, but the supply schedule dimmed its appeal somewhat.
Monday's stock market action shows investors were 'underpricing' Trump’s promised tariffs
Markets sold off on Monday as investors digested Donald Trump's tariff announcements on Mexico, Canada and China.
Sarepta could be down on patient death in FDA database, says RBC Capital
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...
Alliance Pharma downgraded by RBC after weak H2, revenue miss
The downgrade comes after the company reported full-year revenue that fell 4% below market expectations, reflecting an underperformance in the second half of the year.